Safety and efficacy of olutasidenib treatment in elderly patients with relapsed/refractory mIDH1 acute myeloid leukemia

被引：0
|
作者：
De Botton, Stephane
Jonas, Brian Andrew
Ferrell, P. Brent
Chao, Mwe Mwe
Mims, Alice S.
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA USA
[3] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[4] Rigel Pharmaceut Inc, South San Francisco, CA USA
[5] Ohio State Univ, Columbus, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6527
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Preliminary Safety, Efficacy, and Molecular Characterization of Emavusertib (CA-4948) in Relapsed/Refractory Acute Myeloid Leukemia Patients
    Winer, Eric S.
    Sallman, David
    Burguera, Adolfo De la Fuente
    Verma, Amit
    Goetze, Katharina
    Abaza, Yasmin
    Dugan, James P.
    Cluzeau, Thomas
    Arboli, Eduardo Rodriguez
    Mims, Alice
    Groepper, Stefanie
    Zilbershatz, Itay
    Liesveld, Jane L.
    Fiedler, Walter
    Tarantolo, Stefano R.
    Ades, Lionel
    Papadantonakis, Nikolaos
    Schliemann, Christoph
    Choudhary, Gaurav S.
    Lane, Maureen
    Zhao, Wanying
    Jain, Ashish
    Gallagher, Cole
    Garcia-Manero, Guillermo
    BLOOD, 2024, 144 : 738 - 739
  • [42] Progress and strategies for patients with relapsed and refractory acute myeloid leukemia
    Litzow, Mark R.
    CURRENT OPINION IN HEMATOLOGY, 2007, 14 (02) : 130 - 137
  • [43] Prediction of Treatment-Related Mortality in Patients with Relapsed and Refractory Acute Myeloid Leukemia
    Godwin, Colin
    Othus, Megan
    Sandhu, Vicky
    Estey, Elihu H.
    Walter, Roland B.
    BLOOD, 2014, 124 (21)
  • [44] Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments
    Jeffrey C. Bryan
    Elias J. Jabbour
    Drugs & Aging, 2015, 32 : 623 - 637
  • [45] Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments
    Bryan, Jeffrey C.
    Jabbour, Elias J.
    DRUGS & AGING, 2015, 32 (08) : 623 - 637
  • [46] Ivosidenib for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation
    Pasquier, Florence
    Chahine, Claude
    Marzac, Christophe
    de Botton, Stephane
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2020, 5 (06): : 429 - 438
  • [47] Olutasidenib Alone or in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Myelodysplastic Syndromes/Neoplasms (MDS)
    Cortes, Jorge
    Yang, Jay
    Lee, Sangmin
    Dinner, Shira N.
    Wang, Eunice S.
    Baer, Maria R.
    Donnellan, William B.
    Watts, Justin M.
    BLOOD, 2023, 142
  • [48] Safety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours
    Wick, W.
    Tabatabai, G.
    Schuler, M.
    Rorhberg, K.
    Chawla, S. P.
    Janku, F.
    Schiff, D.
    Heinemann, V.
    Narita, Y.
    Ando, Y.
    Lenz, H. J.
    Ikeda, M.
    Genvresse, I.
    Rentzsch, C.
    Reschke, S.
    Cyris, C.
    Cai, C.
    Jeffers, M.
    Pena, C.
    Baehr, O.
    ANNALS OF ONCOLOGY, 2019, 30 : 170 - +
  • [49] COMBINATION OF CLOFARABINE AND CYTARABINE IN THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA
    Spassov, B.
    Balatzenko, G.
    Angelova, S.
    Toshkov, S.
    Guenova, M.
    Arnaudov, G.
    Mihaylov, G.
    HAEMATOLOGICA, 2015, 100 : 377 - 377
  • [50] Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia
    Cui, Longzhen
    Liu, Yan
    Pang, Yifan
    Qian, Tingting
    Quan, Liang
    Cheng, Zhiheng
    Dai, Yifeng
    Ye, Xu
    Pang, Ying
    Shi, Jinlong
    Ke, Xiaoyan
    Wu, Depei
    Fu, Lin
    CANCER GENE THERAPY, 2020, 27 (1-2) : 1 - 14
12345